Karachi: The Special Investment Facilitation Council’s deregulatory measures have significantly boosted Pakistan’s pharmaceutical industry, resulting in a remarkable economic upturn. The policy has led to a profit surge of 13.5 billion rupees, marking a 210 percent increase in the sector.

Key companies within the pharmaceutical industry have reported profit increments of between 44 percent and 339 percent. This surge has made the industry more appealing to investors, with annual exports anticipated to reach five billion dollars, enhancing global investment potential.

The deregulatory framework has facilitated increased transparency in drug pricing and fostered competition, thereby improving access to quality medications. Companies are also being incentivized to invest in innovative research and development of new drugs, with an emphasis on enhancing the production of high-quality pharmaceuticals.

Additionally, the policy prioritizes the prevention of substandard and overpriced drugs, reinforcing consumer protection measures. The pharmaceutical sector’s advancement, underpinned by the SIFC’s initiatives, is regarded as a key driver of economic stability in the country.